secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001104659-25-063028
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise announces positive sevasemten data; FDA provides clear path to first Becker therapy
--------------------------------------------------------------------------------

- MESA OLE: 99% enrollment (85 participants); NSAA scores improved 0.8 pts over 18 months, diverging from natural history declines.
- FDA Type C: NSAA endorsed for traditional approval; CANYON alone insufficient; GRAND CANYON may serve as single pivotal study.
- GRAND CANYON on track for topline data Q4 2026; highly powered to show NSAA difference vs placebo over 18 months.
- Duchenne Phase 2 LYNX/FOX: 10 mg dose selected for Phase 3; well-tolerated; FOX suggests slower decline in post-gene therapy patients.
- Plans to meet FDA Q4 2025 for Phase 3 Duchenne design; pivotal study initiation expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925063028/0001104659-25-063028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925063028/tm2519221d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-063028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer